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Background: Intra-partum cefazolin is used to prevent group B Streptococcus (GBS) vertical transmission in
mothers allergic to penicillin without a history of anaphylaxis.
Objectives: To investigate the maternal cefazolin dose–exposure relationship and subsequent maternal and
neonatal target attainment at delivery.
Methods: Data were obtained from 24 healthy, GBS-colonized pregnant women (20–41 years), undergoing vagi-
nal delivery (gestational age 37 weeks). During labour, all women received a 2 g cefazolin IV infusion. Eight
hours later, eight women received another 1 g in the event of delayed (>8 h) delivery. Next to maternal plasma
concentrations (up to 10 per dosing interval, until delivery), venous and arterial umbilical cord concentrations
were determined at delivery. Target attainment in maternal/neonatal plasma was set at 1 mg/L for 60% of the
dosing interval (unbound cefazolin, worst-case clinical breakpoint). A population pharmacokinetic (popPK) model
was built (NONMEM 7.4). ClinicalTrials.gov Identifier: NCT01295606.
Results: At delivery, maternal blood and arterial umbilical cord unbound cefazolin concentrations were >1 mg/L
in 23/24 (95.8%) and 11/12 (91.7%), respectively. The popPK of cefazolin in pregnant women was described by a
two-compartment model with first-order elimination. Two additional compartments described the venous and
arterial umbilical cord concentration data. Cefazolin target attainment was adequate in the studied cohort,
where delivery occurred no later than 6.5 h after either the first or the second dose. PopPK simulations showed
adequate maternal and umbilical cord exposure for 12 h following the first dose.
Conclusions: PopPK simulations showed that standard pre-delivery maternal cefazolin dosing provided
adequate target attainment up to the time of delivery.
Introduction
Group B Streptococcus (GBS) bacteria is one of the leading causes
of maternal infections during pregnancy and post-partum, as well
as in the neonate.1,2 GBS is a colonizer of the gastrointestinal or
genitourinary tract in about 20% of pregnant women.3 Vertical
GBS transmission from the mother to the neonate occurs during la-
bour or birth in 36% of colonized mothers, which may lead to
meningitis, sepsis and other infections in the neonate.3 Therefore,
antibiotic regimens are administered in mothers, to provide
intra-partum GBS prophylaxis. The antimicrobial of choice for
prophylaxis against GBS infections is penicillin G or amoxicillin. Both
are deemed equally effective.4 However, for women that have
penicillin allergy without a history of anaphylaxis, cefazolin is a
safe and effective alternative in this setting.4,5
Cefazolin is a first-generation cephalosporin that works by
inhibiting bacterial cell wall synthesis. It is only available for IV and
intramuscular administration. Besides GBS prophylaxis, cefazolin is
a standard prophylactic antimicrobial agent for various surgical
interventions, including delivery-related interventions like caesar-
ean section, owing to its broad-spectrum activity against most
Gram-positive bacteria and some Gram-negative bacteria.6 It is
highly bound to serum albumin (75%–85%), with unbound cefazo-
lin available for pharmacological activity.7–11 The efficacy of cefa-
zolin for GBS prophylaxis depends on the time that the unbound
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drug concentration is above the MIC, which is generally less than
1 mg/L for GBS, for 60%–70% of the dosing interval.12–15
Several population pharmacokinetic (popPK) models of cefazo-
lin have been developed in different clinical settings. Two models
described the PK of cefazolin during pregnancy.10,11 Three other
models described the cefazolin PK during caesarean delivery.16–18
There are some data suggesting that labour influences the PK of
antibiotics.19 However, no model described the PK of cefazolin dur-
ing labour and subsequent vaginal delivery. Also, the subsequent
post-delivery early neonatal exposure is unknown. Therefore,
a popPK model will be of relevance, providing insight into the
intra-partum neonatal protection against GBS infections.
The objectives of our work were: (i) to build a popPK model of
cefazolin based on maternal and umbilical cord plasma concen-
trations obtained from women undergoing vaginal delivery; (ii) to
investigate target attainment [time above 4% the epidemiological
cut-off (ECOFF) of 0.25 mg/L] in the mothers during labour; and
(iii) to investigate the early post-partum cefazolin exposure in the
newborn.
Patients and methods
Patients and data collection
Data were obtained from a prospective, exploratory study. The goal of the
study was to obtain insight into target attainment and the PK of cefazolin in
women undergoing vaginal delivery. Healthy singleton pregnant women
were recruited. All women were colonized with GBS and were admitted for
vaginal delivery. During labour, the women received a 2 g cefazolin IV infu-
sion over 30 min. If no delivery occurred 8 h after infusion, a second 1 g
cefazolin infusion was given over 15 min. Maternal blood samples were
obtained following a fixed sampling scheme with maximally 10 samples
per dosing interval (until delivery), plus an additional sample right after de-
livery. Besides maternal blood samples, arterial and venous umbilical cord
blood samples were collected at delivery. Additional data collected were
gestational age, maternal age, maternal bodyweight and birthweight. The
two parents’ informed consents were collected according to the Ethics
Committee approval of the Centre Hospitalier Universitaire de Liège before
sample collection (ClinicalTrials.gov Identifier: NCT01295606).
Analytical procedures
All heparinized blood samples were centrifuged immediately after sam-
pling (10 min, 1200 g, ambient temperature) and plasma was stored at
#80C until further analysis. Cefazolin total plasma concentrations were
measured using HPLC coupled with a diode array detector (‘HPLC-DAD’)
with a lower limit of quantification of 0.5 mg/L. The assay intra-day preci-
sion (expressed as relative standard deviation) varies from 0.9357% to
4.396% depending on concentration (repeatability), while the assay inter-
day precision varies from 1.483% to 5.426% depending on concentration
(intermediate precision).20
PK/pharmacodynamic target
An unbound cefazolin concentration above the MIC throughout at least
60% of the dosing period (i.e. 60% fT>MIC) was used as an optimal PK/phar-
macodynamic target.21 In the absence of an MIC of cefazolin for GBS, we
use the 0.25 mg/L ECOFF of amoxicillin for Streptococcus agalactiae.22,23 To
avoid selecting resistant bacteria, a worst-case target of at least 60%
fT>4%ECOFF was assumed.
Unbound cefazolin concentrations in maternal plasma were calculated
from the measured total concentrations assuming 75% protein binding
(lower limit of the 75%–85% interval, because albumin is known to
decrease in the later stage of pregnancy).10,11
PopPK modelling
Software
Dataset formatting and exploration were performed using R (version 3.5.1,
R Core Team, Vienna, Austria) using custom scripts based on packages
including dplyr and ggplot2.24,25 PopPK analysis was performed using
NONMEM (version 7.4; ICON Development Solutions, Gaithersburg, MD,
USA), with a GNU Fortran 95 compiler and the Perl-speaks-NONMEM (PsN;
version 4.7.0) toolkit on the interface software Pirana (version 2.9.7;
Certara, Inc., Princeton, NJ, USA).
Model development
Parameter estimation was performed using first-order conditional estima-
tion with interaction (FOCE-I) and differential equation solver ADVAN 13.
The precision of the parameter estimates was evaluated based on the root
squared error (RSE).
A base popPK model was developed. Different structural models with
varying numbers of compartments were explored. Individual PK parame-
ters were assumed to be log-normally distributed, which was achieved
using an exponential function. Magnitudes of differences of individual
parameters from the typical value (interindividual variability) and differen-
ces between observed values and model predicted values (residual variabil-
ity) were quantified. The parametrization was performed using an
exponential formula. For example, the clearance parametrization followed
this equation:
CLi ¼ TVCL exp gið Þwith gi  Nð0; x2Þ (Eqn 1)
with CLi the clearance of subject i, TVCL the typical population value of the
clearance, gi the individual subject’s deviation from the typical value and x
2
the variance of inter-subject variability.
The base model was selected based on objective function value (OFV)
comparisons (difference3.84 points; P0.050), Akaike information criter-
ion (difference3.84 points; P0.050), plausibility and precision of param-
eter estimates, and goodness-of-fit plots. A final model, including covariate
effects, was built via a two-way stepwise covariate modelling procedure
(forward inclusion a = 0.010; backward elimination a = 0.001). The tested
covariates were gestational age and maternal bodyweight.
Final model evaluation
The final model was evaluated using a prediction-corrected visual
predictive check (pcVPC; n = 1000 simulated replicates of the original
dataset). Furthermore, bootstrapping was performed to obtain non-
parametric estimates of uncertainty in parameter estimates (n = 2000
bootstraps).
Simulations in newborns
Neonatal exposure after birth in our study cohort was predicted using
Monte Carlo simulations. These simulations were based on the popPK
model-predicted arterial umbilical cord concentrations at birth to en-
able simulations in all 24 cases. Subsequent cefazolin exposure in the
newborns was predicted from the cefazolin popPK model of De Cock et
al.26 The cefazolin PK was simulated 1000 times for each newborn.
Missing neonatal serum albumin was multiply imputed (n = 1000) with
values sampled from a uniform distribution within the range reported
by Smits et al.8 (28.2–43.7 g/L). Postnatal age was set to zero and cur-
rent weight was set equal to the registered birthweight in the current
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Maternal and arterial umbilical cord simulations
PK simulations were performed during standard pre-delivery maternal
cefazolin dosing (see the Patients and data collection section). The mater-
nal exposure and the PTA in arterial umbilical cord plasma were calculated
up to 12 h after the first infusion. Arterial umbilical cord plasma concentra-
tions were considered fetal plasma concentrations, since arterial cord blood
originates directly from the fetal circulation. Based on previous literature,
protein binding was assumed to be 75% in maternal plasma [see the
PK/pharmacodynamic target section] and 60% in neonatal plasma.10,11,26
Results
Patient characteristics
Data were obtained from 24 healthy pregnant women
(20–41 years and bodyweight 70.5–89.7 kg), colonized with GBS,
undergoing vaginal delivery (gestational age 37 weeks). A sum-
mary of participant characteristics is presented in Table 1. During
labour, all women received a 2 g cefazolin IV infusion over 30 min
for prophylaxis against GBS. In 16 women, delivery occurred within
6.5 h after the infusion [median (IQR) = 4.6 (3.3–5.6) h]. Eight hours
after the first administration, the remaining eight women received
a second cefazolin infusion (1 g) over 15 min.
Altogether, the women contributed 245 plasma samples to the
analysis, 24 of which were matched venous and arterial umbilical
cord samples from 12 women (Figure 1). At the time of delivery,
the maternal unbound cefazolin plasma concentrations were above
the 1 mg/L target in 23/24 (95.8%) women [5.82 (1.89–5.86) mg/L]
(Figure S1, available as Supplementary data at JAC Online). The
unbound 1 mg/L target was achieved in 11/12 (91.6%) arterial
umbilical cord samples [5.12 (3.56–5.72) mg/L].
PopPK model
Model development
A two-compartment popPK model with linear elimination best
described the maternal cefazolin concentration data (Table S1).
Two additional compartments were added to represent the ven-
ous and arterial umbilical cord concentrations, with blood flowing
from the maternal central compartment to the venous umbilical
cord compartment, then to the arterial umbilical cord compart-
ment, and then back to the maternal central compartment with
the placenta as a barrier between both (Figure 2).
Interindividual variability was estimated on the maternal clear-
ance [43% coefficient of variation (CV)], central volume of distribu-
tion (67%CV) and peripheral volume of distribution (68%CV). A
mixed error model was selected to describe the residual variability
based on goodness-of-fit plots and the OFV.
Gestational age and body weight were tested as covariates, but
did not significantly improve the OFV or the parameter estimation
accuracy. Therefore, these covariates were not retained in the final
model (Table S2). Parameter estimates from the final model are
shown in Table 2.
Model evaluation
Goodness-of-fit plots showed that the final model adequately
described the observed data (Figure S2 and Figure S3). A pcVPC
showed the good predictive capacity of our model, where the
median values and the 95% CIs of the prediction-corrected
observed data fell within the 95% prediction intervals of the model
(Figure 3). Median values of the non-parametric bootstrap were in
good agreement with point estimates (Table 2).
Simulations in newborns
The PK simulations showed adequate neonatal antimicrobial ex-
posure for protection against GBS in neonates at birth in our study
cohort [3.58 (2.50–4.84) mg/L] (n = 24) (Figure 4). Unbound cefazo-
lin is predicted to remain detectable for at least 24 h after birth.
Maternal and arterial umbilical cord simulations
The PK simulations showed that the median maternal unbound
cefazolin plasma is above the therapeutic target of 1 mg/L for the
entire 12 h simulation period (Figure 5a). The PTA of neonatal (ar-
terial) unbound cefazolin concentrations slowly increases and
reaches 90% or more approximately 1 h after the start of infusion
(Figure 5b).




age (years), median (IQR) 30 (26–32.3)
gestational age (weeks), median (IQR) 39 (39–40)
maternal bodyweight at first cefazolin dose
(kg), median (IQR)
80.5 (70.5–89.7)
birthweight (kg), median (IQR) 3.5 (2.7–4.6)
Cefazolin dosing
cefazolin first dose (mg), median (IQR) 2000 (2000–2000)
cefazolin second dose (mg), median (IQR) 1000 (1000–1000)
number of cefazolin first doses, n 24
number of cefazolin second doses, n 8
Delivery
time between first cefazolin dose and
delivery (h), median (IQR), n (cases)
4.6 (3.3–5.6), 16
time between second cefazolin dose and
delivery (h), median (IQR), n (cases)
0.5 (0.1–1), 8
Sampling information
number of plasma samples, n 254
number of plasma samples/patient, median
(IQR)
10 (9–11)
number of umbilical cord plasma samples,
n (arterial/venous)
24 (12/12)
number of plasma samples below the lower
limit of quantification, n (%)
0 (0)
Cefazolin measurements
cefazolin maternal concentrations (mg/L),
median (IQR)
61 (23.3–99.4)
cefazolin arterial umbilical concentrations
(mg/L), median (IQR)
12.8 (8.9–14.3)
cefazolin venous umbilical concentrations
(mg/L), median (IQR)
12.1 (9–14.35)
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Discussion
In this study, we performed a popPK modelling and simulation
study of cefazolin in healthy women undergoing vaginal delivery
and their newborns. We obtained a better understanding of the
pre-delivery maternal cefazolin dose–exposure relationship and
subsequent post-delivery duration of neonatal target attainment.
Although PK variability is large, fixed 2 g cefazolin dosing—fol-
lowed by 1 g cefazolin 8 h later if delivery had not occurred yet—
provided adequate unbound cefazolin exposure in the mother and
in the neonate at the time of birth.
A two-compartment model with linear elimination best
described the maternal and umbilical cord concentration data. To
the best of our knowledge, no popPK model of cefazolin in women
in labour and subsequently undergoing vaginal delivery has been
published before. However, there are two popPK models describing
the cefazolin PK in women during pregnancy (gestational age
range 17–40 weeks, fetal surgery or caesarean).10,11 Additionally,
three popPK models are available describing cefazolin PK in
women undergoing caesarean delivery.16–18 Two of the previous
models (both caesarean delivery models) used a one-
compartment model to describe the cefazolin popPK.16,17 This
structural difference could be due to the sparse sampling schemes
in these studies, as well as the physiological difference between
vaginal and caesarean deliveries (different volume of distribution
and clearance). In the previously published models, the most com-
mon covariates were maternal bodyweight, gestational age and
maternal albumin. Bodyweight and gestational age were tested,
Figure 1. Total cefazolin concentration versus time after dose. Grey dots, maternal plasma concentrations; blue diamonds, venous umbilical cord
plasma concentrations; red diamonds, arterial umbilical cord plasma concentrations. This figure appears in colour in the online version of JAC and in
black and white in the print version of JAC.
Figure 2. Schematic representation of the pre-delivery maternal-umbilical cord popPK model. art, arterial; CL, clearance; neo, neonatal; Q, blood
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Table 2. Population parameter estimates
Parameter Estimate (%RSE) [%shrinkage] Bootstrap median (95% CI)
Typical values
CLmaternal (L/h) 7.15 (10) 6.99 (3.41–9.03)
Vc (L) 6.23 (19) 6.25 (3.81–8.82)
Q1 (L/h) 26.1 (19) 27.75 (18.56–45.95)
Vp (L) 6.95 (23) 7.05 (4.04–9.71)
Q2 (L/h) 2.61 (16) 2.77 (1.04–6.86)
Vvenous umbilical cord and Varterial umbilical cord/neonatal (L) 6.97 (15) 8.87 (2.57–34.7)
Q3 (L/h) 4.48 (12) 4.85 (1.84–12.48)
Q4 (L/h) 5.47 (14) 5.49 (2.27–10.91)
CLneonatal (L/h) 0 FIXED 0 FIXED
Interindividual variability model
on CL (%CV) 42.9 (16) [10] 45.8 (26.3–80.8)
on Vc (%CV) 66.6 (25) [8] 65.3 (17.9–114.1)
on Vp (%CV) 67.9 (33) [26] 71.8 (22.5–158.3)
Residual variability
additive residual variability (mg/L) (maternal) 0.082 (30) [9] 0.075 (0.034–0.124)
proportional residual variability (%CV) (maternal) 14.7 (43) [9] 19 (5.7–69.9)
additive residual variability (mg/L) (venous) 0.021 (58) [23] 0.014 (2.44%10#6–0.043)
proportional residual variability (%CV) (venous) 0 FIX 0 FIX
additive residual variability (mg/L) (arterial) 0 FIX 0 FIX
proportional residual variability (%CV) (arterial) 9.16 (47) [5] 8.21 (0.43–17.81)
CL, clearance; CV, coefficient of variation calculated as
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
exp x2ð Þ  1
q
 100%; Vc, central volume of distribution; Vp, peripheral volume of distribution.
Figure 3. pcVPC of the final model. The observed prediction-corrected total cefazolin concentrations are represented by circles. The black continuous
and broken lines represent the median and the 2.5th and 97.5th percentiles, respectively, of the prediction-corrected observations. The shaded areas
indicate the 90% prediction intervals of the median and the 2.5th and 97.5th percentiles of the simulated values. This figure appears in colour in the
online version of JAC and in black and white in the print version of JAC.
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but not retained in our model, while serum albumin concentrations
were not available in our study dataset.
Muller et al.19 suggested that physiological changes during la-
bour and subsequent vaginal delivery may influence the maternal
PK of antibiotics (mainly distribution characteristics), as well as
their placental transfer and subsequent fetal and neonatal expos-
ure. Comparing our cefazolin PK parameters during labour with
those reported by others during pregnancy and caesarean deliv-
ery, no clear differences could be observed.17,27 However, a future
popPK model meta-based analysis is warranted to obtain further
insight into potential differences.
Besides maternal PK, Muller et al.19 also indicated the need to
document fetal and neonatal exposure. Our dataset included
samples from the umbilical cord (venous and arterial) at the time
of cord clamping. Unfortunately, no postnatal observations in the
newborns of the mothers recruited were available in our study.
However, similar to Muller et al.,28 we postulated that the arterial
umbilical cord concentrations reflect the neonatal concentrations
at birth. Starting from these model-predicted arterial umbilical
cord concentrations, subsequent neonatal exposure was simu-
lated with the De Cock et al.26 model. Unbound cefazolin was pre-
dicted to remain above 0.5 mg/L for at least 24 h after birth.
Consequently, a blood culture collected within this time frame, for
example because of suspected early-onset sepsis in the newborn,
is more likely to remain false negative.
Although target attainment was adequate in our study cohort,
delivery occurred no later than 6.5 h after the first infusion and 4 h
after the second infusion in all women. Therefore, we performed
PK simulations, calculating the PTA at delivery across the 8 h after
the first infusion and the 4 h after the second infusion (total 12 h
period). These simulations showed that the unbound cefazolin
concentration in the maternal plasma remains above the thera-
peutic target for the entire 12 h period of the simulations per-
formed. Furthermore, the simulations also illustrated the slow
increase in neonatal (arterial umbilical cord) unbound cefazolin
concentrations, such that 90% PTA is reached approximately 1 h
after the start of the first infusion.
Our study had several strengths. First, our dataset included rich
sampling, which enabled the accurate capture of the structural
elements of the popPK model. Second, our data included umbilical
cord samples, which enabled us to have insight into the neonatal
target attainment. Our study had some limitations. First, we were
limited with regard to covariate exploration, because our dataset
had only 24 pregnant women, which limited the ability of our
model to identify covariates. Additionally, we were limited with the
covariates included in our dataset. Only two covariates were
tested in the popPK model building (gestational age and maternal
bodyweight) and both were not retained. In future research, it
would be of interest to test other covariates, such as estimated
glomerular filtration rate and albumin, on the cefazolin PK in this
clinical setting. Another limitation is that our dataset only included
total cefazolin concentrations. The unbound concentrations were
not measured. This limitation hindered our ability to fully explore
the cefazolin maternal protection. Instead, we postulated a
Figure 4. Neonatal unbound cefazolin concentrations versus time since birth. The blue lines each represent the median of 1000 simulations based
on one of the predicted neonatal concentrations from the developed model. The thick black line represents the median trend. The horizontal broken
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cefazolin protein-bound fraction of 75% in the maternal blood as
previously published.9,10
To conclude, we showed that the standard pre-delivery mater-
nal cefazolin dosing provided adequate maternal and neonatal
antimicrobial protection against GBS in our patient cohort up to the
time of delivery. In addition, we developed a popPK model to de-
scribe the cefazolin PK in women during labour with subsequent
vaginal delivery. This popPK model was used for simulations that
showed that standard pre-delivery cefazolin dosing of a 2 g infu-
sion at the start and a 1 g infusion at the eighth hour provides
adequate unbound cefazolin concentrations during the entire 12 h
time window of the simulations.
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